JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa.

Cancer 1997 Februrary 2
BACKGROUND: The Stein-Leventhal syndrome (SLS), first described in 1935, is characterized by infertility, hyperandrogenization, and obesity. Because this phenotype represents an aggregation of risk factors for postmenopausal breast carcinoma, and because in general, a hormonal imbalance underlies the disorder, the authors examined the association between self-reported SLS and breast carcinoma incidence in a cohort of 34,835 cancer-free women assembled in 1986 and followed through 1992.

METHODS: All participants were between the ages of 55 and 69 and held a valid Iowa driver's license. A total of 472 women in the cohort (1.35%) reported a history of SLS at baseline. Incident cases of breast carcinoma were identified annually using the State Health Registry of Iowa. Data were analyzed using Cox proportional hazards regression.

RESULTS: During the follow-up period, there were 883 incident breast carcinomas, 14 among women reporting a history of SLS. Women with SLS were more likely than women without SLS to report fertility problems and menstrual irregularities, but there were no significant differences observed regarding body mass index (BMI). Although women with SLS were 1.8 times as likely to report benign breast disease than women without SLS (P < 0.01), they were not more likely to develop breast carcinoma (relative risk [RR] = 1.2; 95% confidence interval [CI] = 0.7-2). Adjustment for age at menarche, age at menopause, parity, oral contraceptive use, BMI, waist-to-hip ratio, and family history of breast carcinoma lowered the RR to 1 (95% CI = 0.6-1.9.

CONCLUSIONS: Despite the high risk profiles of some women with SLS, these results do not suggest that the syndrome per se is associated with an increased risk of postmenopausal breast carcinoma.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app